Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma.

Konomi Kobayashi Hiroyuki Nagase Naoya SugimotoShiho YamamotoAkihiko Tanaka Koichi Fukunaga Ryo AtsutaEtsuko TagayaMasayuki Hojo Yasuhiro Gonnull null

Published in: Asia Pacific allergy (2021)

This study was the first to show that the levels of serum galectin-10 decreases after initial administration of mepolizumab. The significant relationship between serum ECP and better response in FEV1 suggested the potential role of serum ECP as a predictive biomarker for the efficacy of mepolizumab (UMIN000030466).

Keyphrases

chronic obstructive pulmonary disease
risk assessment
human health
binding protein